Early efforts focused on PIM1 specifically, and a compound with potent PIM1 inhibitory activity, SGI-1776 [28], entered phase 1 clinical evaluation for patients with relapsed or refractory prostate cancer or lymphoma in 2008. The gene discussed is PIM1; the disease is prostate carcinoma.